Telaprevir Phase IIb Data Continues To Support 24-Week Dosing For Hepatitis C, Vertex Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PROVE-2 data show 65 percent sustained viral response in treatment naive patients, Vertex reports.